课题基金 / 基金详情

Identification and molecular characterization of anti-diabetic flavonoids

Identification and molecular characterization of anti-diabetic flavonoids
抗糖尿病黄酮类化合物的鉴定和分子表征
批准号:
8820798
负责人:
DONGMIN LIU
金额:
$37.92万
依托单位国家:
美国
项目类别:
财政年份:
2012
资助国家:
美国
项目状态:
已结题
起止时间:
2012-03-01 至 2016-02-29

项目摘要

项目成果

DONGMIN LIU的其他基金

相似基金

相关文献

中文摘要
翻译
描述(由申请人提供):本研究的长期目标是识别和表征可以有效预防2型糖尿病(T2D)的天然药物。T2D是慢性胰岛素抵抗和β细胞质量和功能丧失的结果。因此,同时预防胰岛素抵抗和保护功能性β细胞群的方法可能是预防T2D的更有效策略。我们首次发现,大豆和一些中草药中含有的染料木素(genistein)可直接保护糖尿病小鼠胰岛β细胞免于凋亡,改善高血糖,而不影响胰岛素敏感性;银杏叶中含有的黄酮醇山奈酚(kaempferol)可改善肥胖小鼠的胰岛素敏感性和葡萄糖稳态。值得注意的是,染料木黄酮与山奈酚组合对中年肥胖糖尿病小鼠的血糖控制产生有效的累加效应。我们使用这个年龄的小鼠,因为T2D通常发生在人类的中年和老年。这些令人兴奋的发现证明了使用这些天然化合物有效预防T2D的巨大潜力。本申请的目的是确定染料木黄酮和山奈酚发挥抗糖尿病作用的分子机制。该授权的中心假设是染料木黄酮和山奈酚两者的膳食摄入同时保持功能性β细胞质量并改善胰岛素敏感性,从而在预防T2D中发挥累加效应。目的#1将确定金雀异黄素是否通过G蛋白偶联受体GPR30介导的G α s活化以及随后的cAMP/PKA/CREB和PI3K/Akt通路的刺激来保护β细胞凋亡。分离的小鼠和人胰岛将用于鉴定染料木黄酮靶向的信号分子。具体而言,将利用GPR30缺陷型小鼠以及遗传和药理学探针来探索这些途径是否介导染料木黄酮在β细胞中的抗凋亡作用。目的#2将探索染料木黄酮,山奈酚, 或两者的组合对胰腺β-细胞功能、能量代谢和胰岛素敏感性以及体内这些作用的潜在分子机制的影响。我们将首先 使用GPR30缺陷型糖尿病小鼠来确定染料木黄酮是否通过该受体改善葡萄糖稳态和β细胞存活和质量。然后,我们将测试山奈酚是否促进能量代谢和胰岛素敏感性,以及这些作用是否通过激活AMPK α介导,AMPK α是细胞能量稳态的主要调节因子,也是T2D的潜在治疗靶点。完成这项资助有望确定染料木黄酮和山奈酚发挥抗糖尿病作用的新机制,这可能会导致开发使用这些低成本天然化合物预防糖尿病的补充或替代(CAM)策略,糖尿病是美国和世界范围内一个主要且日益严重的公共卫生问题。
英文摘要
DESCRIPTION (provided by applicant): The long-range goal of this research is to identify and characterize natural agents that can effectively prevent type 2 diabetes (T2D). T2D is a result of chronic insulin resistance and loss of β-cell mass and function. Therefore, a method to simultaneously prevent insulin resistance and protect functional β-cell mass could be a more effective strategy to prevent T2D. We discovered for the first time that genistein, an isoflavone present in soybean and some Chinese herbs, directly protect pancreatic β-cells from apoptosis and ameliorates hyperglycemia without affecting insulin sensitivity in diabetic mice, while kaempferol, a flavonol present in gingko biloba, improves insulin sensitivity and glucose homeostasis in obese mice. Notably, genistein in combination with kaempferol produces a potent additive effect on blood glycemic control in middle-aged obese diabetic mice. We used mice at this age because T2D usually occurs at middle and older age in humans. These exciting findings demonstrate a great potential for using these natural compounds to effectively prevent T2D. The goal of this application is to determine molecular mechanisms by which genistein and kaempferol exert an anti-diabetic effect. The central hypothesis of this grant is that dietary intae of both genistein and kaempferol simultaneously preserves functional β-cell mass and improves insulin sensitivity, thereby exerting the additive effect in preventing T2D. Aim #1 will determine whether genistein protects against β-cell apoptosis through the G-protein coupled receptor GPR30-mediated activation of Gαs, and subsequent stimulation of the cAMP/PKA/CREB and PI3K/Akt pathways. Isolated mouse and human islets will be used to identify the signaling molecules targeted by genistein. Specifically, GPR30-deficient mice and genetic and pharmacological probes will be utilized to explore whether these pathways mediate the anti-apoptotic action of genistein in β-cells. Aim #2 will explore the effects of genistein, kaempferol, or a combination of both on pancreatic beta-cell function, energy metabolism, and insulin sensitivity as well as the underlying molecular mechanisms for these actions in vivo. We will first use GPR30-deificent diabetic mice to determine whether genistein improves glucose homeostasis and β-cell survival and mass via this receptor. We will then test whether kaempferol promotes energy metabolism and insulin sensitivity and whether these effects are mediated via activation of AMPKα, a master regulator of cellular energy homeostasis and potential therapeutic target for T2D. Completion of this grant is expected to define novel mechanisms by which genistein and kaempferol exert the anti-diabetic effects, which may potentially lead to the development of complementary or alternative (CAM) strategies using these low-cost natural compounds for the prevention of diabetes, a major and growing public health problem in the U.S. and worldwide.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Discovery and characterization of a novel natural product for the treatment of both diabetes and obesity
Identification and molecular characterization of anti-diabetic flavonoids
Identification and molecular characterization of anti-diabetic flavonoids
Identification and molecular characterization of anti-diabetic flavonoids
海外基金